A 61-year-old woman with type 2 diabetes and chronic heart failure (EF 40%) presents to fast-track with 3 days of productive cough, fever and right-sided pleuritic pain. She has not taken antibiotics in the past 3 months and has no recent hospitalization or history of MRSA or Pseudomonas. She is alert and oriented. Vital signs: T 38.4 C, HR 96, RR 20, BP 132/78, SpO2 95% on room air. BUN is 16 mg/dL, glucose 214 mg/dL. Chest radiograph shows a right lower lobe infiltrate. She tolerates oral intake and lives with her husband. Question: Which outpatient antibiotic regimen is MOST appropriate? A. Amoxicillin monotherapy B. Azithromycin monotherapy C. Amoxicillin-clavulanate plus doxycycline D. Admission for IV vancomycin plus cefepime CORRECT ANSWER: C. Amoxicillin-clavulanate plus doxycycline RATIONALE: Her CURB-65 score is 0 (no confusion, BUN under 20, RR under 30, normal blood pressure, age under 65) and she is oxygenating well, so outpatient treatment is appropriate. The 2019 ATS/IDSA community-acquired pneumonia guideline stratifies outpatients by comorbidity. Healthy adults without comorbidities may receive amoxicillin, doxycycline or, where pneumococcal macrolide resistance is under 25%, a macrolide alone. Patients with chronic heart, lung, liver or renal disease, diabetes, alcohol use disorder, malignancy or asplenia need broader coverage: a beta-lactam (amoxicillin-clavulanate or cefpodoxime/cefuroxime) plus a macrolide or doxycycline, or monotherapy with a respiratory fluoroquinolone. This combination covers Streptococcus pneumoniae, beta-lactamase-producing Haemophilus influenzae and Moraxella, and atypical organisms. She has no risk factors for MRSA or Pseudomonas. Discharge instructions should include glucose monitoring, heart failure precautions and follow-up within 48-72 hours. WHY THE OTHER ANSWERS ARE INCORRECT: A. Amoxicillin alone is appropriate for a healthy outpatient without comorbidities, but it lacks atypical coverage and beta-lactamase stability, which are needed in patients with diabetes and heart failure. B. Macrolide monotherapy is acceptable only for healthy adults in regions with low pneumococcal macrolide resistance. It is inadequate for a patient with significant comorbidities. C. Correct answer (see rationale above). D. Broad-spectrum anti-MRSA and antipseudomonal therapy is reserved for severe CAP with prior MRSA/Pseudomonas isolation or recent hospitalization with IV antibiotics. It exposes this low-risk patient to unnecessary toxicity and resistance pressure. CLINICAL PEARL: Outpatient CAP with comorbidities: beta-lactam (amoxicillin-clavulanate or a cephalosporin) plus a macrolide or doxycycline, or a respiratory fluoroquinolone alone. RED FLAG / CANNOT-MISS POINT: Undertreating a comorbid patient with narrow monotherapy, or reflexively escalating to anti-MRSA/antipseudomonal agents without risk factors, both violate evidence-based CAP care. DIFFICULTY: Moderate COGNITIVE LEVEL: Application AANPCB DOMAIN I (PRACTICE): 03 Patient Management — Prescribe appropriate pharmacologic agents AANPCB DOMAIN II (PATIENT CONDITION): Thoracic-Respiratory Disorders CLINICAL DOMAIN: Infectious disease and sepsis POPULATION: Adult PRIMARY DIAGNOSIS OR CONCEPT: Outpatient CAP antibiotic selection with comorbidities TINTINALLI REFERENCE: Tintinalli's Emergency Medicine, 9th ed. — topic: Pneumonia and Pulmonary Infiltrates. Exact chapter citation should be verified against Tintinalli's Emergency Medicine, 9th Edition. REFERENCES: Tintinalli, J. E., Ma, O. J., Yealy, D. M., Meckler, G. D., Stapczynski, J. S., Cline, D. M., & Thomas, S. H. (Eds.). (2020). Tintinalli's emergency medicine: A comprehensive study guide (9th ed.). McGraw Hill. Topic: Pneumonia and Pulmonary Infiltrates. Walls, R. M., Hockberger, R. S., Gausche-Hill, M., Erickson, T. B., & Wilcox, S. R. (Eds.). (2023). Rosen's emergency medicine: Concepts and clinical practice (10th ed., Vols. 1-2). Elsevier. Topic: Pneumonia.